EGFR and non-small cell lung carcinoma: A study also suggests that in EGFR wild-type NSCLC, TAZ-driven amphiregulin (AREG) expression triggers the activation of the EGFR signaling pathway, and Gefitinib induced sensitization in EGFR wild-type NSCLC [61].